CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Schrodinger Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Schrodinger Inc
1540 BROADWAY, 24TH FLOOR
Phone: (503) 299-1150p:503 299-1150 NEW YORK, NY  10036  United States Ticker: SDGRSDGR
Business Summary
Schrodinger, Inc. operates a physics-based computational platform that enables the discovery of molecules for drug development and materials applications. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. The Company operates through two segments: Software and Drug Discovery. The Software segment is focused on selling its software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment is focused on building a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The Company's pipeline of drug discovery programs includes SGR-1505 (MALT1 Inhibitor), SGR-2921 (CDC7 Inhibitor), SGR-3515 (WEE1 Inhibitor). Its software was used by researchers around the world at more than 1,760 academic institutions.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023YesYes---

Industries
SIC Code Description
7372 Prepackaged software
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board MichaelLynton 64 10/1/2018 1/11/2018
President, Chief Executive Officer, Director RamyFarid 59 1/1/2017 1/1/2008
Chief Financial Officer, Executive Vice President GeoffreyPorges 63 8/18/2022 8/18/2022
9 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
XTAL BioStructures, Inc. 12 Michigan Dr Natick Massachusetts United States

Business Names
Business Name
Faxian Therapeutics, LLC
Reo Discovery Limited
Schrodinger India Private Limited
7 additional Business Names available in full report.

General Information
Number of Employees: 867 (As of 2/5/2024)
Outstanding Shares: 72,858,767 (As of 11/5/2024)
Shareholders: 104
Stock Exchange: NASD
Federal Tax Id: 954284541
Fax Number: (302) 655-5049


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, December 3, 2024